Active Ingredient History
Insulin glargine, a long-acting form of insulin, was marketed under the brand name LANTUS. Lantus is indicated for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. The primary activity of insulin glargine is regulation of glucose metabolism. It lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. The off-label use of insulin glargine is the treatment type 2 diabetes in children and the treatment of gestational diabetes. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Angiogenesis Modulating Agents (Phase 3)
Atherosclerosis (Phase 3)
Auditory Diseases, Central (Phase 4)
Blood Glucose (Phase 4)
Cardiovascular Diseases (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 3)
Cystic Fibrosis (Phase 4)
Delivery, Obstetric (Phase 1)
Diabetic Foot (Phase 4)
Diabetic Ketoacidosis (Phase 4)
Diabetic Retinopathy (Early Phase 1)
Endothelial Cells (Phase 4)
General Surgery (Phase 4)
Glucose Metabolism Disorders (Phase 4)
Glycemic Control (Phase 3)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 4)
Hospitalization (Phase 4)
Hypercholesterolemia (Phase 3)
Hyperglycemia (Phase 4)
Hypertension (Phase 3)
Hypoglycemia (Phase 4)
Insulin (Phase 3)
Intestinal Neoplasms (Phase 4)
Kidney Failure, Chronic (Phase 4)
Leukemia (Phase 3)
Liver Cirrhosis (Phase 4)
Lymphoma (Phase 3)
Metabolic Diseases (Phase 4)
Myocardial Infarction (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Overweight (Phase 3)
Peripheral Vascular Diseases (Phase 4)
Pharmacology (Phase 4)
Prediabetic State (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Stroke (Phase 3)
Varicose Ulcer (Phase 3)
Venous Cutdown (Phase 3)
Wound Healing (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
